Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
ECOG-ACRIN Cancer Research Group
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT06112613
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Intervention
Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring, Interview, Patient Navigation, Survey Administration, Text Message-Based Navigation Intervention
Condition
Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Investigators
Gelareh Sadigh, John M. Schallenkamp, Ilana Graetz, Maria T. Grosse-Perdekamp, Pamala A. Pawloski, Charissa K. Williams, Deborah W. Wilbur, Jay W. Carlson, Joseph J. Merchant, Site Public Contact